Periodic Reporting for period 1 - JEM Phase 1 (JEM: The world safest subcutaneous, enclosed, biocompatible implantable device, attached directly to a AV fistula or graft or vein, for chronic disease patients in need of repetitive vascular access)

Summary
➢ Millions of chronic disease patients worldwide depend on treatment that requires safe, repetitive access to the vascular system. The major markets are dialysis and oncology patients in need of chemotherapy. Other chronic disease patients, who require regular medications or...
More information & hyperlinks